Katrina Farrell

Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle

Anne Hamilton, Joseph P. Eder, Anne C. Pavlick et al. · Journal of Clinical Oncology · 2005 · 100 citations

Medicine, Oncology, Pharmacology +15

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations

Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman et al. · Journal of Clinical Oncology · 2024 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network

Katrina Farrell, Pam McKay, Mike Leach · Leukemia & lymphoma/Leukemia and lymphoma · 2011 · 26 citations

Medicine, Hematology, Oncology +17

An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events

Katrina Farrell, Andrew Fyfe, Jonathan Allan et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 26 citations

Medicine, Hematology, Pediatrics +16

Cervical Amyloidoma Successfully Treated With Bortezomib and Dexamethasone

Katrina Farrell, David Stobo, Richard Soutar · Journal of Clinical Oncology · 2011 · 10 citations · Full text

Medicine, Oncology, Pharmacotherapy +13